Emergent BioSolutions (EBS) Depreciation and Depletion (2021 - 2026)

Emergent BioSolutions' Depreciation and Depletion history runs 6 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• In Q1 2026, Depreciation and Depletion fell 23.08% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at $28.6 million (down 30.41% YoY), while the FY2025 annual figure was $30.7 million, down 29.75% from the prior year.
• Depreciation and Depletion was $7.0 million for Q1 2026 at Emergent BioSolutions, down from $7.2 million in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $28.5 million in Q2 2022 to a low of $7.0 million in Q1 2026.
• Historically, Depreciation and Depletion has averaged $13.2 million across 5 years, with a median of $11.7 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Depreciation and Depletion soared 54.05% in 2022, then sank 42.36% in 2023.
• A 5-year view of Depreciation and Depletion shows it stood at $18.0 million in 2022, then fell by 25.56% to $13.4 million in 2023, then fell by 27.61% to $9.7 million in 2024, then fell by 25.77% to $7.2 million in 2025, then declined by 2.78% to $7.0 million in 2026.
• The last three Depreciation and Depletion figures came in at $7.0 million (Q1 2026), $7.2 million (Q4 2025), and $7.1 million (Q3 2025), per Business Quant data.